Differential expression of DNA topoisomerase IIα and -β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1869-1876

  Withoff, S ^a   De Vries, E G E ^a   Keith, W N ^b   Nienhuis, E F ^a   Van Der Graaf, W T A ^a   Uges, D R A ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; GLC4; Multidrug resistance; Topoisomerase II ; Topoisomerase II

Indexed keywords

AMSACRINE; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FOSTRIECIN; GLYCOPROTEIN P; ISOENZYME; MESSENGER RNA; MITOXANTRONE; TENIPOSIDE;

ARTICLE; CANCER CELL CULTURE; CROSS RESISTANCE; DRUG ACCUMULATION; ENZYME ASSAY; GENE LOSS; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030470414     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.647     Document Type: Article

References (47)

1. ASANO T, HERZOG CE, MAYES J, MCWATTERS A, ZWELLING L AND KLEINERMAN ES. (1995). Transfection of a Drosophila topoisomerase II gene sensitizes an intrinsically resistant human brain tumor cell line to etoposide. Proc. Am. Assoc. Cancer Res., 36, 2637.
2. AUSTIN CA, SNG JH, PATEL S AND FISHER LM. (1993). Novel HeLa topoisomerase II is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases. Biochim. Biophys. Acta, 1172, 283-291.
3. BECK J, NIETHAMMER D AND GEKELER V. (1994a). High mdr1-and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett., 86, 135-142.
4. BECK WT, DANKS MK, WOLVERTON JS, CHEN M, GRANZEN B, KIM R AND SUTTLE DP. (1994b). Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv. Pharmacol., 29B, 145-169.
5. BORITZKI TJ, WOLFARD TS, BESSERER JA, JACKSON RC AND FRY DW. (1988). Inhibition of type II topoisomerase by fostriecin. Biochem. Pharmacol., 37, 4063-4068.
6. COLE SPC, BHARDWAY G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAN AMV AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant lung cancer cell line. Science, 258, 1650-1654.
7. COUTTS J, PLUMB JA, BROWN R AND KEITH WN. (1993). Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br. J. Cancer, 68, 793-800.
8. COVEY JM, KOHN KW, KERRIGAN D, TILCHEN KJ AND POMMIER Y. (1988). Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res., 48, 860-865.
9. D'ANDREA MR, MULTHAUPT HAD, FARBER PA AND FOGLESON PD. (1995). Expression of genes for DNA topoisomerase IIα and DNA Topoisomerase IIβ in human tumours. Proc. Am. Assoc. Cancer Res., 36, 2690.
10. DANKS MK, QIU J, CATAPANO CV, SCHMIDT CA, BECK WT AND FERNANDES DJ. (1994). Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM26. Biochem. Pharmacol., 48, 1785-1795.
11. DEFFIE AM, BATRA JK AND GOLDENBERG GJ. (1989). Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49, 58-66.
12. DE JONG S, ZIJLSTRA JG, DE VRIES EGE AND MULDER NH. (1990). Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistanT human small cell lung carcinoma cell line. Cancer Res., 50, 304-309.
13. DE JONG S, ZIJLSTRA JG, MULDER NH AND DE VRIES EGE. (1991). Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother. Pharmacol., 28, 461-464.
14. DE JONG S, KOOISTRA AJ, DE VRIES EGE, MULDER NH AND ZIJLSTRA JG. (1993). Topoisomerase II as a target of VM26 and 4′-(9-acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res., 53, 1064-1071.
15. DOKTER WHA, ESSELINK MT, HALIE MR AND VELLENGA E. (1993). Interleukin-4 inhibits the lipoplysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. Blood, 81, 337-343.
16. DRAKE FH, HOFMANN GA, BARTUS HF, MATTERN MR, CROOKE ST AND MIRABELLI CK. (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28, 8154-8160.
17. FELDHOFF PW, MIRSKI SEL, COLE SPC AND SULLIVAN DM. (1994). Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung carcinoma cell line. Cancer Res., 54, 756-762.
18. FLENS MJ, IZQUIERDO MA, SCHEFFER GL, FRITZ JM, MEIJER CJLM, SCHEPER RJ AND ZAMAN GJR. (1994). Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54, 4557-4563.
19. FRY AM, CHRESTA CM, DAVIES SM, WALKER MC, HARRIS AL, HARTLEY JA, MASTERS JRW AND HICKSON ID. (1991). Relationship between topoisomerase II level and chemosensitivity in human tumour cell lines. Cancer Res., 51, 6592-6595.
20. GUCHELAAR HJ, TIMMER-BOSSCHA H, DAM-MEIRING A, UGES DRA, OOSTERHUIS JW, DE VRIES EGE AND MULDER NH. (1993). Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int. J. Cancer, 55, 442-447.
21. HARKER WG, SLADE DL, PARR RL, FELDHOFF PW, SULLIVAN DM AND HOLGUIN MH. (1995). Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res., 55, 1707-1716.
22. HOWARD MT, NEECE SH, MATSON SW AND KREUZER KN. (1994). Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc. Natl Acad. Sci. USA, 91, 12031-12035.
23. KALLIONIEMI OP, KALLIONIEMI A, KURISU W, THOR A, CHEN LC, SMITH HS, WALDMAN FM, PINKEL D AND GRAY JW. (1992). ErbB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl Acad. Sci. USA, 89, 5321-5325.
24. KIMURA K, SAIJO M, UI M AND ENOMOTO T. (1994). Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J. Biol. Chem., 269, 1173-1176.
25. LEHRACH H. (1990). Genetic and physical mapping. In Genome Analysis. Vol. I, Davies KE and Tilghman SM. (eds) pp. 39-81. Cold Spring Harbor Laboratory Press: New York.
26. LING V. (1992). P-glycoprotein and resistance against anticancer drugs. Cancer, 69, 2603-2609.
27. LIU LF. (1989). DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375.
28. MA L, KRISHNAMACHARY N AND CENTER MS. (1995). Phosphorylation of the multidrug resistance protein gene encoded protein P190. Biochemistry, 34, 3338-3343.
29. MCPHERSON JP, BROWN GA, DEUCHARS KL AND GOLDENBERG GJ. (1995). Increased sensitivity to adriamycin in drug-resistance P388 murine leukemia cells transfected with human Topoisomerase IIα. Proc. Am. Assoc. Cancer Res., 36, 2641.
30. MEIJER C, MULDER NH, TIMMER-BOSSCHA H, ZIJLSTRA JG AND DE VRIES EGE. (1987). Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res., 47, 4613-4617.
31. MÜLLER M, MEIJER C, ZAMAN GJR, BORST P, SCHEPER RJ, MULDER NH, DE VRIES EGE AND JANSSEN PLM. (1994). Overexpression of the gene encoding the multidrug resistant-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl Acad. Sci. USA, 91, 13033-13037.
32. MURPHY DS, MCHARDY P, COUTS J, MALLON EA, GEORGE WD, KAYE SB, BROWN R AND KEITH WN. (1995). Interphase cytogenetic analysis of crbB2 and topoIIα co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int. J. Cancer, 64, 18-26.
33. NITISS JL, LIU YX, HARBURY P, JANNATIPOUR M, WASSERMAN R AND WANG JC. (1992). Amsacrine and etoposide hypersensitivity of yeast overexpressing DNA topoisomerase II. Cancer Res., 52, 4467-4472.
34. POMMIER Y, LETEURTRE F, FESEN MR, FUJIMORI A, BERTRAND R, SOLARY E, KOHLHAGEN G AND KOHN KW. (1994). Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12, 530-542.
35. TAN KB, DORMAN TE, FALLS KM, CHUNG, TDY, MIRABELLI CK, CROOKE ST AND MAO JL (1992). Topoisomerase-IIα and topoisomerasc-IIβ genes - characterization and mapping to human chromosome-17 and chromosome-3, respectively. Cancer Res., 52, 231-234.
36. TIMMER-BOSSCHA H, HOSPERS GAP, MEIJER C, MULDER NH, MUSKIET FAJ, MARTINI IA, UGES DRA AND DE VRIES EGE. (1989). Influence of docosahexanoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J. Natl Cancer Inst., 81, 1069-1075.
37. VAN DER GRAAF WTA, DE VRIES EGE, TIMMER-BOSSCHA H, MEERSMA GJ, MESANDER G, VELLENGA E AND MULDER NH. (1994). Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res., 54, 5368-5373.
38. VAN DER ZEE AGJ, WITHOFF S, KRANS M AND DE VRIES EGE. (1995). DNA topoisomerase I, IIα and IIβ protein and RNA expression levels in human ovarian carcinoma. Proc. Am. Assoc. Cancer Res., 36, 2671.
39. 4 sublines with increasing adriamycin resistance. Int. J. Cancer, 61, 375-380.
40. WITHOFF S, SMIT EF, MEERSM GJ, VAN DEN BERG A, TIMMER-BOSSCHA H, KOK K, POSTMUS PE, MULDER NH, DE VRIES EGE AND BUYS CHCM. (1994). Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a Polymerase Chain Reaction-aided transcript titration assay. Lab. Invest., 71, 61-66.
41. WITHOFF S, KEITH WN, KNOL AJ, COUTTS JC, HOARE SF, MULDER NH AND DE VRIES EGE. (1996). Selection of subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell line panel. Br. J. Cancer, 74, 502-507.
42. WOESSNER RD, CHUNG TDY, HOFMANN GA, MATTERN MR, MIRABELLI CK, DRAKE FH AND JOHNSON RK. (1990). Differences between normal and ras-transformed N1H-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res., 50, 2901-2908.
43. WOESSNER RD, MATTERN MR, MIRABELLI CK, JOHNSON RK AND DRAKE FH. (1991). Proliferation- and cell-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff., 2, 209-214.
44. YAMAZAKI K, ISOBE H, OGURA S AND KAWAKAMI Y. (1995). Topoisomerase IIα content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase inhibitors in lung cancer cell lines. Proc. Am. Assoc. Cancer Res., 36, 2663.
45. ZAMAN GJR, FLENS MJ, VAN LEUSDEN MR, DE HAAS M, MULDER HS, LANKELMA J, PINEDO HM, SCHEPER RJ, BAAS F, BROXTERMAN HJ AND BORST P. (1994). The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl Acad. Sci. USA, 91, 8822-8826.
46. ZIJLSTRA JG, DE VRIES EGE AND MULDER NH. (1987). Multi-factorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47, 1780-1784.
47. ZINI N, SANTI S, OGNIBENE A, BAVELLONI A, NERI L-M, VALMORI A, MARIANI E, NEGRI C, ASTALDI-RICOTTI GCB AND MARALDI NM. (1994). Discrete localization of different DNA topoisomerascs in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res., 210, 336-348.